Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual - 2Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
- 3Bombardier Global 8000 Enters Service
- 4At least 36 dead in major fire in Hong Kong residential blocks
- 5What are the health benefits of whole milk for kids?
- Disney's latest short film 'Versa' tackles a difficult subject: Pregnancy loss. It's resonating with viewers.
- At 72, Kathie Lee Gifford says aging isn’t what she expected. 'The golden years? It’s a lie.’
- 2 new malaria treatments announced as drug resistance grows
- 2024 Style: The It-Things You Want in Your Closet
- Investigating Design and Individual Style: Track down Your Remarkable Look
- Tanzania president remorseful over internet shutdown on election day
- NASA's Artemis 2 moon launch may be visible from Florida and southern Georgia today. Here's when to look
- Partake in the Outside: Senior-Accommodating Exercises for 2024
- Scientists may be overestimating the amount of microplastics in the environment – and the culprit is lab gloves
